NPY, neuropeptide Y, 4852

N. diseases: 381; N. variants: 12
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease BEFREE All these results suggest that NPY and Y2R in the mPFC are involved in the pathophysiology of depression and NPY plays an antidepressant role in the mPFC mainly via Y2R, which suppresses the NLRP3 signaling pathway, in LPS-induced depression model rats. 31736656 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 AlteredExpression disease BEFREE Clinical specimens from patients with prostate cancer with higher score of depression revealed higher CD68<sup>+</sup> TAM infiltration and stronger NPY and IL6 expression. 30504424 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease BEFREE Neuropeptide Y is a peptide neuromodulator with protective roles including anxiolytic and antidepressant-like effects in animal models of depression and post-traumatic stress disorder. 31082535 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease BEFREE In addition to this decrease in depression-like behavior, brain-derived neurotrophic factor (BDNF) and neuropeptide Y (NPY) release increased in the hippocampus in response to MAI treatment, but estradiol levels did not recover. 29643431 2018
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 AlteredExpression disease BEFREE At t<sub>1</sub>, increased mean levels of NPY in CSF significantly correlated with impaired performance in most ISR scores (ISR total p = .018, depression p = .035, anxiety p = .008, nutrition disorder p = .047, supplementary items p = .038) and in several psychological SF-36 items (vitality p = .019, general mental health p = .001, mental component summary p = .025). 30213237 2018
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease BEFREE In this review, we present an overview of findings with regard to the NPY system in relation to anxiety and stress, acute as well as chronic; furthermore we discuss post-traumatic stress disorder and, in part depression. 28824541 2017
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 AlteredExpression disease BEFREE Furthermore, the behavioral indicators of depression showed strong correlations with the serum levels and the hippocampal content of NPY. 28582442 2017
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease BEFREE Both NPY and CGRP were higher in PD patients with comorbid depression compared to MDD patients. 28659833 2017
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease PSYGENET Among all candidate substrates, DPP4 displays highest affinity for NPY, an endogenous anxiolytic neurotransmitter that is suggested as a candidate biomarker in post-traumatic stress disorder (PTSD) and depression. 25635612 2015
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease PSYGENET Using a recombinant adeno-associated viral (rAAV) vector, we addressed this idea by testing effects on anxiolytic- and depression-like behaviours in adult mice after overexpression of NPY transgene in the amygdala and/or hippocampus, two brain regions implicated in emotional behaviours. 25267070 2014
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease BEFREE NPY has recently gained much attention as an endogenous antiepileptic and antidepressant agent, as drugs with antiepileptic and/or mood-stabilizing properties may exert their action by increasing NPY concentrations, which in turn can reduce anxiety and depression levels, dampen seizures or increase seizure threshold. 23994577 2013
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease PSYGENET However, alterations in anxiety- and depression-regulating genes were present in the hypothalamus of BACHD mice including reduced mRNA expression of neuropeptide Y, tachykinin receptor 3 and vesicular monoamine transporter type 2 as well as increased expression of cocaine and amphetamine regulated transcript. 23697793 2013
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 GeneticVariation disease BEFREE Statistical analysis showed a significant correlation between the SNP sites rs16139 in NPY and the morbidity of depression. 23468908 2013
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 AlteredExpression disease BEFREE However, alterations in anxiety- and depression-regulating genes were present in the hypothalamus of BACHD mice including reduced mRNA expression of neuropeptide Y, tachykinin receptor 3 and vesicular monoamine transporter type 2 as well as increased expression of cocaine and amphetamine regulated transcript. 23697793 2013
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease PSYGENET Statistical analysis showed a significant correlation between the SNP sites rs16139 in NPY and the morbidity of depression. 23468908 2013
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease PSYGENET These data suggest that changes of plasma levels of anti-NPY autoAbs are relevant to altered mood, while changes of their affinity may participate in altered appetite and body weight in patients with depressive disorder. 22365482 2012
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 AlteredExpression disease BEFREE These data suggest that changes of plasma levels of anti-NPY autoAbs are relevant to altered mood, while changes of their affinity may participate in altered appetite and body weight in patients with depressive disorder. 22365482 2012
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 GeneticVariation disease BEFREE Five NPY gene variants were investigated for an influence on antidepressant treatment response in a sample of 256 patients with depression. 19854625 2010
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease BEFREE However, novel evidence from polymorphisms in the prepro-NPY gene has shed new light on the potential clinical relevance of NPY in depression. 19782662 2010
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 GeneticVariation disease BEFREE Pro7 allele of preproNPY protected against depression among Swedes. 19264362 2009
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease BEFREE The data support our hypothesis that the NPY system dysregulation constitutes one of the biological underpinnings of depression and that one common mechanism of action of antidepressive treatment modalities may be effects on NPY and its receptors. 17572454 2007
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease CTD_human The data support our hypothesis that the NPY system dysregulation constitutes one of the biological underpinnings of depression and that one common mechanism of action of antidepressive treatment modalities may be effects on NPY and its receptors. 17572454 2007
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Therapeutic disease CTD_human The data support our hypothesis that the NPY system dysregulation constitutes one of the biological underpinnings of depression and that one common mechanism of action of antidepressive treatment modalities may be effects on NPY and its receptors. 17572454 2007
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease BEFREE Neuropeptide Y (NPY) was shown to modulate anxiety- and depression-related behaviors in various animal models. 16691011 2006
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.600 Biomarker disease BEFREE For example, NPY is consistently involved in anxiety-related behaviors and there is increasing support for a role of this peptide in mood disorders such as depression. 16611091 2006